Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients. 1997

E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
Institute of Laboratory Medicine Donauspital, Vienna, Austria.

Aberrant expression of CD44 splice variants has been detected on a variety of human tumor cells. Overexpression of specific isoforms has been shown to be associated with metastasis and poor prognosis in breast cancer. We evaluated the possible utility of soluble CD44 splice variant v5 (sCD44v5) as a circulating, tumor-associated marker in breast cancer patients. Serum levels of sCD44v5 were determined in 147 healthy volunteers, in 53 patients with nonmalignant breast disease, in 85 patients with breast cancer at presentation, in 13 patients with recurrence and in 73 patients with active metastatic disease. Statistically, the levels at presentation in stages I-IV, in benign disease, and in a female control group were not significantly different. First longitudinal studies over 1-2 years in the follow-up of 28 patients who have remained tumor-free showed considerable between-patient variation while the intrapatient levels remained within relatively narrow limits. In patients with active metastatic disease, elevated levels of sCD44v5 (> 58 ng.ml-1) were detected in 50% of the cases with marked elevation in only 26%. In these cases, sCD44v5 correlated with the extent of metastatic disease and fell during clinical response to cytoreductive therapy. In comparison with CA15-3 in the patients' follow-up serum levels of sCD44v5 proved to be much less sensitive concerning lead time, percentage of raised serum levels at the time of recurrence and in metastatic disease. The value of sCD44v5 determinations in breast cancer patients was further limited by the poor diagnostic specificity of this marker due to elevated levels in smokers and chronic inflammatory disease.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017398 Alternative Splicing A process whereby multiple RNA transcripts are generated from a single gene. Alternative splicing involves the splicing together of other possible sets of EXONS during the processing of some, but not all, transcripts of the gene. Thus a particular exon may be connected to any one of several alternative exons to form a mature RNA. The alternative forms of mature MESSENGER RNA produce PROTEIN ISOFORMS in which one part of the isoforms is common while the other parts are different. RNA Splicing, Alternative,Splicing, Alternative,Alternate Splicing,Nested Transcripts,Alternate Splicings,Alternative RNA Splicing,Alternative RNA Splicings,Alternative Splicings,Nested Transcript,RNA Splicings, Alternative,Splicing, Alternate,Splicing, Alternative RNA,Splicings, Alternate,Splicings, Alternative,Splicings, Alternative RNA,Transcript, Nested,Transcripts, Nested
D018396 Mucin-1 Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer. Antigen CA-15-3,CA-15-3 Antigen,Episialin,Epithelial Membrane Antigen,Epithelial Mucin, Polymorphic,Muc1 Mucin,Polymorphic Epithelial Mucin,Antigens, CD227,CA 15-3 Antigen,CA 15.3 Antigen,CD227 Antigen,Antigen CA 15 3,Antigen, CA 15-3,Antigen, CA 15.3,Antigen, CA-15-3,Antigen, CD227,Antigen, Epithelial Membrane,CA 15 3 Antigen,CA-15-3, Antigen,CD227 Antigens,Membrane Antigen, Epithelial,Mucin 1,Mucin, Muc1,Mucin, Polymorphic Epithelial
D018960 Hyaluronan Receptors Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary THYMOCYTES; GRANULOCYTES; MACROPHAGES; erythrocytes, and fibroblasts. Their interaction with HYALURONIC ACID mediates binding of lymphocytes to high endothelial VENULES. Antigens, CD44,CD44 Antigens,Hyaluronan-Binding Protein,Receptors, Hyaluronan,CD44 Antigen,Chondroitin Sulfate Proteoglycan 8,Hyaluronan Receptor,Hyaluronic Acid Binding Protein,Antigen, CD44,Hyaluronan Binding Protein,Receptor, Hyaluronan

Related Publications

E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 1997, Anticancer research,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 1998, Anticancer research,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 2003, Medical and pediatric oncology,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 2001, Oncology reports,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
August 1997, International journal of cancer,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 1998, Breast cancer research and treatment,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
February 2003, Cancer research and treatment,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 2015, Growth factors (Chur, Switzerland),
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
January 1997, British journal of cancer,
E M Kittl, and R Ruckser, and S Selleny, and V Samek, and J Hofmann, and K Huber, and A Reiner, and E Ogris, and W Hinterberger, and K Bauer
November 2000, International journal of molecular medicine,
Copied contents to your clipboard!